Stage FocusSeries A, Series B+
GeographyEurope, US
TypeGrowth Equity
Last Activity2026
Industry Focus
Industries
Biotech
Technical BenchStrong
Investor TypeDeepTech Purist
ExposureMostly DeepTech Investments
Bio
Jeito Capital is a biopharma investment firm founded in 2018 by Dr. Rafaèle Tordjman, a hematologist and former INSERM research scientist with more than 20 years investing in life sciences. Based in Paris with a second team in the United States, the firm manages roughly 1.6 billion euros through a group of 30-plus multidisciplinary healthcare professionals covering the full drug-development value ...
Notable Investments
S
SparingVisionP
PulmocideN
Neogene TherapeuticsE
EyeBioN
NMD PharmaN
Noema PharmaQ
Quell TherapeuticsA
Alentis TherapeuticsB
BionyraH
HI-BioO
Odyssey TherapeuticsX
XyloCor TherapeuticsSimilar Funds
Advent Life Sciences
London, United Kingdom
Pure DeepTechBiotechMedtechSeedSeries A
Apollo Health Ventures
Berlin, Germany
Pure DeepTechBiotechSeedSeries A
Flagship Pioneering
Cambridge, United States
Pure DeepTechBiotechAgritechAIPre-SeedSeed
Forbion
Naarden, Netherlands
Pure DeepTechBiotechSynthetic BiologyClimate TechSeedSeries A
Korify Capital
Basel, Switzerland
Pure DeepTechBiotechNeurotechHardwareSeries ASeries B+
+ND Capital
Woodside, CA, United States
Pure DeepTechBiotechAdvanced MaterialsSemiconductorsSeedSeries A